{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fcdh6-adcs-GtXXAtTO","width":444,"version":"1.0","type":"rich","title":"CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/1de1052b-b521-466c-80dc-3c7065c18170/100855-cdh6-ovarian-research-focus-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b03425ff-ab7d-4c5d-b20d-9a8d9cb3c3d9\" height=\"200\" width=\"100%\" title=\"CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Learn about the emerging role of CDH6-targeting antibody–drug conjugates for ovarian cancer with Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard MD, PhD, discussing the latest results and implications of studies evaluating raludotatug deruxtecan and other agents."}